Supporting vasculitis descriptive vaccine
Patrizia Felicetti(Italian Medicines Agency), Jan Bonhoeffer(University Children’s Hospital Basel), Caterina Bonetto(Italian Medicines Agency), Saša Živković(University of Pittsburgh), Barbara Pahud(Children's Mercy Hospital), Novilia Sjafri Bachtiar(PT Bio Farma (Indonesia)), Sonali Kochar, Merita Kukucu, Giovanna Zanoni(Azienda Ospedaliera Universitaria Integrata Verona), Carmela Santuccio(Italian Medicines Agency), Robert D. M. Hadden(Erasmus MC), David Burgner(The University of Melbourne), Frederick Varricchio(Rutgers, The State University of New Jersey), Yolanda Brauchli Pernus, Francesco Trotta(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), Linny Kimly Phuong(Royal Children's Hospital), Rebecca E. Chandler(Uppsala Monitoring Centre), Karina A. Top(Dalhousie University), Amina Teeba, Seza Özen(Hacettepe University), Robert P. Wise(Center for Biologics Evaluation and Research), Giuseppe Monaco(Regione Lombardia), Giampiero Girolomoni(University of Verona)
Unknown
January 1, 2015
Cited by 0
Related Papers
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
|Arthritis & Rheumatism|2012|6.6k
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Regulatory Activity of Autocrine IL-10 on Dendritic Cell Functions
|The Journal of Immunology|2001|553
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
|Journal of the European Academy of Dermatology and Venereology|2022|419